Sutro biopharma

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies sutro biopharma cytokine derivatives targeting immuno-oncology pathways.

Key events shows relevant news articles on days with large price movements. Gossamer Bio Inc. GOSS 4. Kezar Life Sciences Inc. KZR 0. Ovid Therapeutics Inc. OVID 0.

Sutro biopharma

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. Vaxcyte, Inc. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the third quarter of , its recent business highlights, and a preview of select anticipated milestones. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the second quarter of , its recent business highlights, and a preview of select anticipated milestones. PT in New York City. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the first quarter of , its recent business highlights, and a preview of select anticipated milestones. Sutro Biopharma Appoints Dr.

Cash from financing Net cash used or generated in financing activities such as dividend payments and loans.

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology. Learn More. Sutro Biopharma, Inc. Our Technology. Our innovative Research and development has resulted in six product candidates Our Pipeline Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro was named one of Fierce Biotech's Fierce 15 in Contents move to sidebar hide.

Reticent crossword clue

Total number of common shares outstanding as of the latest date disclosed in a financial filing. Free cash flow. Vaxcyte Inc. Read Edit View history. PT in New York City. ALLK 7. CTMX 0. South San Francisco. Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. PCVX 0. Please help improve this article by adding citations to reliable sources. Avg Volume. Net cash used or generated in investing activities such as purchasing assets.

.

The average number of shares traded each day over the past 30 days. Hidden categories: Articles with short description Short description is different from Wikidata Articles needing additional references from April All articles needing additional references Articles containing potentially dated statements from All articles containing potentially dated statements Articles with ISNI identifiers. Shares outstanding. Sutro Biopharma, Inc. Many thanks to our Sutro team for their continuous efforts in placing our patients first. Contents move to sidebar hide. XOMA 1. Korn Ferry. The total amount of income generated by the sale of goods or services related to the company's primary operations. PMC South San Francisco. KZR 0. Leadership Team. Total equity The value of subtracting the total liabilities from the total assets of a company. Peninsula Bridge.